CoChat
Sign Up
Cited by 164Tuberculosis Research and EpidemiologyImmune responses and vaccinationsInfectious Diseases and Tuberculosis

The DOI matches its Crossref record; 208 of the 209 references it cites were found in a registry or an index.

Tuberculosis Vaccines and Prevention of Infection

Open access
Hawn, Thomas R., Day, Tracey A., Scriba, Thomas J., Hatherill, Mark, Hanekom, Willem A., Evans, Thomas G., Churchyard, Gavin J., Kublin, James G., Bekker, Linda-Gail, Self, Steven G.·2014·Microbiology and Molecular Biology Reviews
DOI 10.1128/mmbr.00021-14PMC PMC4248657
Open this paper in CoChat — free account

Abstract

SUMMARY: Tuberculosis (TB) is a leading cause of death worldwide despite the availability of effective chemotherapy for over 60 years. Although Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination protects against active TB disease in some populations, its efficacy is suboptimal. Development of an effective TB vaccine is a top global priority that has been hampered by an incomplete understanding of protective immunity to TB. Thus far, preventing TB disease, rather than infection, has been the primary target for vaccine development. Several areas of research highlight the importance of including preinfection vaccines in the development pipeline. First, epidemiology and mathematical modeling studies indicate that a preinfection vaccine would have a high population-level impact for control of TB disease. Second, immunology studies support the rationale for targeting prevention of infection, with evidence that host responses may be more effective during acute infection than during chronic infection. Third, natural history studies indicate that resistance to TB infection occurs in a small percentage of the population. Fourth, case-control studies of BCG indicate that it may provide protection from infection. Fifth, prevention-of-infection trials would have smaller sample sizes and a shorter duration than disease prevention trials and would enable opportunities to search for correlates of immunity as well as serve as a criterion for selecting a vaccine product for testing in a larger TB disease prevention trial. Together, these points support expanding the focus of TB vaccine development efforts to include prevention of infection as a primary goal along with vaccines or other interventions that reduce the rate of transmission and reactivation.

Overview

Integrity signals

Registry

Crossref · 10.1128/mmbr.00021-14

Cites

208 of 208 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 209 references

Research works printed but not linked: 5

  1. WHO. 2013. Global tuberculosis report. WHO, Geneva, Switzerland.
  2. SutherlandI. 1968. The ten-year incidence of clinical tuberculosis following “conversion” in 2550 individuals aged 14 to 19 years. KNCV Tuberculosis Foundation, The Hague, The Netherlands.
  3. RiederHL. 1999. Epidemiological basis of tuberculosis control. International Union against Tuberculosis and Lung Disease, Paris, France.
  4. 2009. WHO. WHO report: global tuberculosis control: surveillance, planning, financing, global report. World Health Organization, Geneva, Switzerland.
  5. GelienJHammanL. 1913. The subsequent history of 1000 patients who recieved tuberculin tests. Bull. Johns Hopkins Hosp. 24:180–186.

Cited by

Sorted by citations

Items 101–162 of 162

Related

See all

Metadata

Authors
Hawn, T. R., Day, T. A., Scriba, T. J., Hatherill, M., Hanekom, W. A., Evans, T. G., Churchyard, G. J., Kublin, J. G., Bekker, L.-G., & Self, S. G.
Affiliations
  • University of Washington (US)
  • Fred Hutch Cancer Center (US)
  • University of Cape Town (ZA)
  • Gates Foundation (US)
  • Aeras (US)
  • University of the Witwatersrand (ZA)
ORCID
Venue
Microbiology and Molecular Biology Reviews
Publisher
American Society for Microbiology
Published
2014-12
Volume
78
Issue
4
Pages
650-671
ISSN
  • 1092-2172 (ISSN-L)
  • 1098-5557
DOI
10.1128/mmbr.00021-14
PMC
PMC4248657
OpenAlex
W2137780892
Cited by
164
References
209
Citations by year
2026: 3 · 2025: 8 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 14 · 2020: 15 · 2019: 21 · 2018: 22 · 2017: 23 · 2016: 20 · 2015: 6
FWCI
2.27
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Microbiology and Molecular Biology Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust (84323)
  • National Institute of Allergy and Infectious Diseases (UM1AI068614, UM1AI068635)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
tuberculosis vaccine development, BCG vaccine, protective immunity, natural resistance to infection, correlates of immunity, tuberculosis transmission, tuberculosis reactivation, tuberculosis epidemiology
MeSH terms
Animals, Clinical Trials as Topic, Humans, Models, Theoretical, Mycobacterium bovis, Mycobacterium tuberculosis, Tuberculosis, Vaccination, HIV Infections, Models, Animal, Tuberculosis Vaccines, Coinfection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review